A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis.
Gabrielle BecherSophia ConnerJennifer A IngramKaren E StephenAlison C McInnesAdrian H HealdPaul A RileyMark DaviesArnau DomenechIsmail KasujeePublished in: Dermatology and therapy (2022)
In UK clinical practice, tildrakizumab was well tolerated and effective at doses of 100 mg or 200 mg in a range of patient phenotypes.